Table 2 Amounts of PB, PBMCs, and CD34+-enriched cells used for reprogramming
Healthy donor and patients (hiPSC line) | Amounts of PB and cryopreserved PBMCs used for hiPSC generation (% of live PBMCs after thawing) | No. of CD34+-enriched cells for transfection | |
|---|---|---|---|
Healthy (TkPP2) | – | 1.0 × 107 cells | 15,000 |
SLE (TkSLE3) | 8.8 mL | 0.4 × 107 cells (33%) | 13,000 |
SLE (TkSLE4) | 18.4 mL | 1.0 × 107 cells (50%) | 16,000 |
SLE (TkSLE5) | 7.5 mL | 1.0 × 107 cells (71%) | 39,375 |
PM (TkSPD3) | 7.5 mL | 0.5 × 107 cells (52%) | 11,500 |
PM (TkSPD4) | 4.2 mL | 1.0 × 107 cells (61%) | 12,5000 |
PM (TkSPD5) | 8.8 mL | 1.0 × 107 cells (38%) | 14,000 |
X-CGD (TkSCG3) | 13.1 mL | 1.0 × 107 cells (53%) | 24,700 |
X-CGD (TkSCG4) | 8.5 mL | 1.0 × 107 cells (56%) | 9000 |
PID (TkSPR1) | 5.3 mL | 1.0 × 107 cells (76%) | 18,000 |
PID (TkSPR2) | 7.7 mL | 1.0 × 107 cells (38%) | 31,000 |
JIA (TkSCR1) | 4.2 mL | 1.0 × 107 cells (65%) | 33,375 |
CMS (TkS42–1) | 13.9 mL | 1.0 × 107 cells (21%) | 5500 |
MD (TkSmD1) | 20.0 mL | 1.0 × 107 cells (12%) | 63,000 |
MD (TkSmD3) | 4.7 mL | 0.5 × 107 cells (56%) | 55,000 |
KCS2 (TkSKCII2) | 4.8 mL | 0.5 × 107 cells (68%) | 42,000 |